Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2017-09-01 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
国浩律师（上海）事务所关于哈药集团股份有限公司股权激励计划调整首次授予限制性股票回购价格、回购注销部分限制性股票以及授予预留部分限制性股票事项之法律意见书
Regulatory Filings
2017-09-01 Chinese
关于向激励对象授予首期限制性股票激励计划预留部分限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the granting of reserved restricted stock under a stock incentive plan by 哈药集团股份有限公司. It includes specifics about the stock grant date, number of shares, pricing, conditions, performance targets, and legal and financial advisor opinions. The content focuses on the company's stock incentive plan implementation and related approvals, rather than financial results or earnings. It is not a full financial report, earnings release, or management discussion. It is also not a proxy statement or voting results announcement. The document is a formal announcement of a capital/financing activity related to stock incentives and equity grants to employees and management. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (6352 characters) and detailed content support this classification with high confidence.
2017-09-01 Chinese
独立董事关于限制性股票激励计划预留部分授予事项的独立意见
Governance Information Classification · 95% confidence The document is an independent opinion from the independent directors of 哈药集团股份有限公司 regarding the granting of reserved restricted stock under a stock incentive plan. It discusses compliance with relevant laws and company regulations, the number of shares granted, the grant date, and the appropriateness of the recipients. This is a governance-related document focused on stock incentive plan approval and compliance, not a financial report or announcement of voting results. It does not contain financial statements or earnings data, nor is it a proxy solicitation or remuneration report. The content fits best under Governance Information (CGR) as it details internal governance procedures related to stock incentives.
2017-09-01 Chinese
关于对限制性股票回购价格进行调整的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from 哈药集团股份有限公司 regarding the adjustment of the repurchase price of restricted stock under its stock incentive plan. It details board and supervisory meetings, independent director opinions, legal opinions, and the rationale for adjusting the repurchase price due to dividend distribution. The document is a formal announcement of a corporate action related to stock incentive plans and repurchase price adjustments, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive content about the adjustment and approvals. It fits best under Capital/Financing Update (CAP) as it relates to changes in capital structure and stock incentive plan terms.
2017-09-01 Chinese
独立董事关于对限制性股票回购相关事项的独立意见
Transaction in Own Shares Classification · 95% confidence The document is an independent opinion from the independent directors of 哈药集团股份有限公司 regarding the repurchase of restricted shares. It discusses the legality and compliance of the repurchase price adjustment and the repurchase and cancellation of restricted shares. The document is a formal opinion letter from independent directors, not a financial report, earnings release, or regulatory filing. It is specifically about a transaction involving the company's own shares (restricted stock repurchase). Therefore, the document fits best under the category of Transaction in Own Shares (POS). The document length is short and focused on this specific matter, confirming it is not a full report or announcement of a report publication.
2017-09-01 Chinese
七届二十六次董事会决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed by the board of directors of 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.) regarding the granting and repurchase of restricted stock under an equity incentive plan. It includes voting results and references to related announcements published on the Shanghai Stock Exchange website. The content focuses on board decisions about stock incentives and repurchases, which is typical of Board/Management Information filings. The document is relatively short (1718 characters) and does not contain detailed financial statements or comprehensive financial data, so it is not an Annual Report or Interim Report. It is not a proxy solicitation or voting results declaration since it is about board resolutions rather than shareholder votes. Therefore, the most appropriate classification is Board/Management Information (MANG).
2017-09-01 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.